Disruption of neurotransmitter vesicle dynamics (transport, capacity, release) has been
implicated in a variety of neurodegenerative and neuropsychiatric conditions. Here, we report a …

Dopamine was first identified as a neurotransmitter localized to the midbrain over 50 years
ago. The dopamine transporter ( DAT ; SLC 6A3) and the vesicular monoamine transporter 2 …

Members of the synaptic vesicle glycoprotein 2 (SV2) family of proteins are involved in
synaptic function throughout the brain. The ubiquitously expressed SV2A has been widely …

Vesicular trafficking defects, particularly those in the autophagolysosomal system, have
been strongly implicated in the pathogenesis of Parkinson’s disease and related α-…

The psychostimulant methamphetamine (METH) is highly addictive and neurotoxic to dopamine
terminals. METH toxicity has been suggested to be due to the release and accumulation …

Preferential dysfunction/degeneration of midbrain substantia nigra pars compacta (SNpc)
dopaminergic (DA) neurons contributes to the main movement symptoms manifested in …

Despite a movement away from dopamine-focused Parkinson’s disease (PD) research, a
recent surge of evidence now suggests that altered vesicular storage of dopamine may …

Mitochondrial and metabolic dysfunction are often implicated in neurological disease, but
effective mechanism-based therapies remain elusive. We performed a genome-scale forward …

The vesicular monoamine transporter 2 (VMAT2) packages neurotransmitters for release
during neurotransmission and sequesters toxicants into vesicles to prevent neuronal damage. …

Drugs of abuse induce sensitization, which is defined as enhanced response to additional
drug following a period of withdrawal. Sensitization occurs in both humans and animal …